{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Acute bacterial skin and skin structure infections",
      "Cellulitis with abscess",
      "Purulent cellulitis",
      "Staphylococcus aureus skin infection",
      "Suppurative cellulitis"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33303329",
  "DateCompleted": {
    "Year": "2021",
    "Month": "10",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "29"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "12",
        "Day": "07"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.idc.2020.10.003",
      "S0891-5520(20)30082-9"
    ],
    "Journal": {
      "ISSN": "1557-9824",
      "JournalIssue": {
        "Volume": "35",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Mar"
        }
      },
      "Title": "Infectious disease clinics of North America",
      "ISOAbbreviation": "Infect Dis Clin North Am"
    },
    "ArticleTitle": "Staphylococcal Skin and Soft Tissue Infections.",
    "Pagination": {
      "StartPage": "81",
      "EndPage": "105",
      "MedlinePgn": "81-105"
    },
    "Abstract": {
      "AbstractText": [
        "Staphylococcus aureus is the most common bacteria causing purulent skin and soft tissue infections. Many disease-causing S aureus strains are methicillin resistant; thus, empiric therapy should be given to cover methicillin-resistant S aureus. Bacterial wound cultures are important for characterizing local susceptibility patterns. Definitive antibiotic therapy is warranted, although there are no compelling data demonstrating superiority of any one antibiotic over another. Antibiotic choice is predicated by the infection severity, local susceptibility patterns, and drug-related safety, tolerability, and cost. Response to therapy is expected within the first days; 5 to 7\u00a0days of therapy is typically adequate to achieve cure."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020 Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA, USA; Division of HIV, Harbor-UCLA Medical Center, Torrance, CA, USA; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: Timothy.hatlen@lundquist.org."
          }
        ],
        "LastName": "Hatlen",
        "ForeName": "Timothy J",
        "Initials": "TJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA, USA; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Harbor-UCLA Medical Center, 1000 West Carson Street, Box 466, Torrance, CA 90509, USA."
          }
        ],
        "LastName": "Miller",
        "ForeName": "Loren G",
        "Initials": "LG"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Infect Dis Clin North Am",
    "NlmUniqueID": "8804508",
    "ISSNLinking": "0891-5520"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "microbiology",
        "therapy"
      ],
      "DescriptorName": "Abscess"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Algorithms"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "microbiology",
        "therapy"
      ],
      "DescriptorName": "Cellulitis"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Drainage"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "microbiology",
        "therapy"
      ],
      "DescriptorName": "Impetigo"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Methicillin Resistance"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Methicillin-Resistant Staphylococcus aureus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [
        "diagnosis",
        "microbiology",
        "therapy"
      ],
      "DescriptorName": "Soft Tissue Infections"
    },
    {
      "QualifierName": [
        "diagnosis",
        "microbiology",
        "therapy"
      ],
      "DescriptorName": "Staphylococcal Skin Infections"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Staphylococcus aureus"
    }
  ],
  "CoiStatement": "Disclosure Dr L.G. Miller has received grants from Merck. Dr T.J. Hatlen has nothing to disclose."
}